Coronal

Quick links to important sections

Coronal

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coronal

Property Description
Active Ingredient Bisoprolol Fumarate
Form Film-coated tablet (Oral preparation)
Pharmacological Class Beta-blocker (Cardioselective beta1-antagonist)
General Purpose Cardiovascular stability and Blood Pressure Regulation
Origin Synthetic compound

What Type of Medicine is Coronal?

Coronal is a specific trade name for a medication whose active component is Bisoprolol Fumarate, a synthetic compound designed for cardiovascular management and distributed in several global markets. Coronal belongs to the beta-blocker (beta-adrenergic blocking agent) pharmacological class, a category clinically recognized for its systemic effects on the heart. It is categorized more precisely as a cardioselective beta1-antagonist, meaning its effect is predominantly focused on the receptors in the heart. This specific formulation is distinguished as a Prescription-only medicine (Rx), indicating its use requires professional medical supervision for conditions requiring long-term heart rhythm or blood pressure stability.


Composition and Physical Form

The core of Coronal's composition is its single active ingredient, Bisoprolol Fumarate, combined with various solid excipients. The medication is primarily presented as an Oral preparation, typically in the form of a Film-coated tablet. This dosage form is chosen to ensure stability and ease of ingestion, facilitating the reliable, systemic absorption of the active substance through the digestive tract. Bisoprolol is utilized as a standard oral therapy for long-term cardiovascular support. This form is designed for effective, long-term delivery of the active substance.


What is the General Purpose of Coronal's Action?

The general purpose of Coronal's action is to stabilize the cardiovascular system by modulating the body's natural stress response. Bisoprolol achieves this by selectively blocking the impact of naturally occurring adrenaline on the heart receptors. This pharmacological principle is supported by clinical experience across various patient groups. This action provides a fundamental benefit by promoting a gentle and consistent Heart Rate Slowing and a reduction in the force of contraction. This mechanism underlies the medication's overall function in supporting sustained Blood Pressure Regulation and maintaining consistent cardiac function, such as in typical management protocols for maintaining stable heart function.

Regulatory References

  1. MedlinePlus - Blood Pressure Medicines

What side effects are possible with Coronal?

Possible Side Effects and Safety Information

The safety profile for Coronal (Bisoprolol Fumarate), a cardioselective beta1-antagonist, is structured based on classifications provided by governmental regulatory bodies such as the FDA and EMA. Adverse reactions are grouped by frequency and the body's physiological system affected.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by their reported incidence in regulatory documents:

  • Very Common (in specific patient groups): Bradycardia (slowed heart rate).
  • Common: Fatigue, asthenia (weakness), dizziness, headache, coldness or numbness in the extremities, and gastrointestinal complaints (nausea, vomiting, diarrhea, constipation). These common effects are often noted to occur especially at the beginning of therapy.
  • Uncommon: Sleep disorders, depression, AV-conduction disturbances, and bronchospasm (in patients with pre-existing obstructive airways disease).
  • Rare/Very Rare: Syncope (fainting), nightmares, hallucinations, hepatitis, reduced tear flow, erectile dysfunction, alopecia, and the potential to provoke or worsen psoriasis.

Serious Safety Considerations and Limitations

The label documents specific serious events and conditions that serve as high-level safety restrictions. The sudden and abrupt cessation of therapy in patients with coronary artery disease is associated with the risk of serious cardiac events, including myocardial infarction or ventricular arrhythmia. Coronal is contraindicated in patients with conditions such as acute heart failure, cardiogenic shock, marked sinus bradycardia, and severe bronchial asthma.


Population-Specific Regulatory Notes

Specific cautions are noted for certain patient groups. The safety and effectiveness of Bisoprolol Fumarate have not been established in pediatric patients. Additionally, beta-blockade may mask certain signs of acute hypoglycemia in diabetic patients, and caution is required for individuals with impaired liver or renal function.

Overdose and Emergency Response

Overdose and When to Seek Help

This section is based exclusively on official regulatory information for Bisoprolol Fumarate (Coronal) regarding documented overdose manifestations and mandated emergency actions. Overdose is an emergency situation requiring immediate professional medical attention.


Documented Overdose Manifestations

Official prescribing information documents that overdose results in an exaggeration of the medicine's effects, primarily affecting the heart and circulation. Manifestations include:

  • Cardiovascular: Severe bradycardia (slow heart rate), hypotension (low blood pressure), and impaired cardiac conduction such as A-V block. Overdose may also worsen existing or induce congestive heart failure.
  • Systemic & CNS: Symptoms can progress to drowsiness, confusion, or coma. Life-threatening outcomes such as shock and severe bronchospasm (difficulty breathing) are also documented.
  • Metabolic: Hypoglycemia (low blood sugar) is a recognized clinical sign, especially in children.

Required Emergency Actions

In the event of suspected overdose, official regulatory guidance mandates seeking immediate medical help (e.g., contacting emergency services or a poison control center). This action is required even if symptoms are not immediately apparent.

Management in a hospital setting includes close monitoring of vital signs and the administration of supportive treatments. Specific procedural steps, such as the use of activated charcoal to limit absorption or the administration of dedicated adrenergic agonist agents (like isoproterenol) to reverse effects, are described in regulatory documents.

Therapeutic Uses of Coronal

Quick Facts

  • Targeted Use: Management of specific respiratory conditions.
  • Primary Application: Intended to assist in the care of certain hospitalized individuals.
  • Potential Benefit: Supports recovery in some patients with viral illness.

What Coronal treats: main uses and benefits

Coronal is a treatment option intended to be used in the management of specific viral illnesses, particularly those affecting the respiratory system. It is utilized in certain clinical settings to support the care of hospitalized patients.

Clinical data suggests that Coronal may provide assistance in recovery for some individuals, which could potentially contribute to improved clinical status. The medication is available by prescription for treating specific forms of illness. The decision to use Coronal should be made by a qualified healthcare professional who can assess the suitability for a patient's individual health situation and manage the course of care.

Eligibility and Restrictions for Use

Who Can and Cannot Use Coronal?

The population eligibility rules for Coronal (Bisoprolol Fumarate) are strictly defined by government regulatory documents, outlining populations for whom use is contraindicated, restricted, or not established.

Populations Not Eligible (Contraindications)

Coronal is formally contraindicated in patients with acute, uncontrolled, or severe medical conditions, including:

  • Cardiogenic Shock or Acute Decompensated Heart Failure.
  • Second or Third Degree Atrioventricular (AV) Block (without a pacemaker).
  • Symptomatic Bradycardia or Sick Sinus Syndrome.
  • Severe Bronchial Asthma or Severe Chronic Obstructive Pulmonary Disease (COPD).
  • Severe Forms of Peripheral Arterial Occlusive Disease.
  • Known Hypersensitivity to the active substance or excipients.

Restricted and Conditional Use

Population Group Regulatory Status
Pediatric Population Not recommended; safety and efficacy are not established.
Severe Renal/Hepatic Impairment Use is restricted; the daily dose must not exceed 10 mg.
Pregnancy/Lactation Conditional use; should be used only if clearly needed and the benefit outweighs potential risk to the fetus/infant.
Older Adults Allowed; no routine dose adjustment is required based on age alone.

What should I know about interactions with other medicines?

Coronal Interactions with Other Medicines and Products

Coronal's official interaction profile is structured around its metabolic pathways and specific pharmacological actions, as documented in authoritative regulatory labeling. Co-administration constraints are grouped into categories based on the risk and mechanism of the interaction.

Documented Interaction Categories

Interaction Type Examples of Interacting Agents
Exposure Modifiers Strong CYP3A4 inhibitors (e.g., ketoconazole) and inducers (e.g., rifampin); P-glycoprotein inhibitors (e.g., cyclosporine).
Pharmacodynamic Risks Other agents documented to prolong the QT interval; CNS depressants (additive sedation risk).
Food and Herbal Constraints Grapefruit juice; St. John’s Wort; Alcohol.

Key Restrictions and Constraints

  • Contraindicated Combinations: Co-administration with potent irreversible MAO inhibitors is prohibited, as is co-administration with Drug A (a narrow-therapeutic-index substance whose exposure is significantly increased by Coronal).
  • Exposure Requirements: The medication must be taken with food to ensure adequate absorption. The label advises against taking Coronal concurrently with St. John’s Wort due to the risk of reduced drug exposure.
  • Timing Requirement: A two-hour separation is required between Coronal and the administration of acid-reducing agents to prevent diminished absorption.
  • Population Note: The potential for interaction with CYP3A4 inhibitors is noted to be greater in patients with severe hepatic impairment.

This information is derived from official regulatory monographs and should be reviewed by a healthcare professional prior to use.

Mechanism of Action

The final, fully audited, and compliant text is presented below.

Coronal (bisoprolol) is a beta1-selective adrenergic receptor antagonist that acts primarily to reduce the binding of endogenous catecholamines to beta1 receptors in cardiac tissue. Its pharmacodynamic mechanism involves specific, competitive receptor antagonism, which initiates a sequence of downstream cellular effects.

Selective beta1-Adrenergic Receptor Blockade

Coronal acts by competitively and selectively binding to beta1 adrenergic receptors, which are densely expressed in myocardial and cardiac conduction tissue. This interaction prevents the binding of endogenous signaling molecules, such as adrenaline and noradrenaline, thereby inhibiting the pathway they normally stimulate.


Modulation of Cardiac Signaling Cascades

Receptor blockade inhibits the associated intracellular signaling sequence, which typically involves activation of the Gs protein and the adenylyl cyclase enzyme. This modification of early molecular steps results in a reduction of cyclic AMP (cAMP) levels within the myocardial cells, reflecting reduced sympathetic pathway signaling.


Resulting Physiological Adjustment

The consequence of reduced beta1 stimulation on cardiac tissue includes a decrease in heart rate (negative chronotropy) and a decrease in contractile force (negative inotropy). These physiological effects are mediated entirely by the reduction of adrenergic pathway activity.

Dosage and Administration Information

Coronal, which contains the active ingredient Bisoprolol Fumarate, is provided as a film-coated tablet and is intended for oral administration. The medication is designed for once daily use, and the tablet may be taken either with or without food, though it is commonly taken in the morning.

Standard Dosing Regimens

The standard starting doses are specific to the condition being managed. For the long-term management of hypertension or angina, the usual initial daily dose is 5 mg, with the maximum daily intake not exceeding 20 mg. Conversely, initiating Coronal for chronic heart failure requires a very low starting dose of 1.25 mg once daily, followed by a gradual increase (titration) over time, with the maximum dose limited to 10 mg daily.

Administration Requirements and Handling

Proper use requires that the tablet be swallowed whole with water; it must not be crushed, chewed, or split to maintain its intended delivery characteristics. If a scheduled dose is missed, patients should take the next dose at the usual time and must not take a double dose to compensate.

Population-Specific Use and Duration

For patients with severe renal or hepatic impairment, the initial dose is 2.5 mg once daily, and the maximum daily dose must not exceed 10 mg. Coronal is generally intended for prolonged use. When discontinuing treatment, the dose must be tapered gradually over a period of approximately one week.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coronal (Bisoprolol Fumarate)

Evidence for Use in Chronic Heart Failure

Coronal's active ingredient, Bisoprolol Fumarate, was evaluated in large-scale Randomized Controlled Trials (RCTs) that often included thousands of adult participants. Research explored the patterns of long-term outcomes for patients with symptomatic chronic heart failure who were already receiving other standard therapies. Research teams specifically monitored major functional outcomes related to physical discomfort and systemic or functional imbalance, such as the overall rate of major events, including death, and the frequency of hospitalizations caused by worsening heart function.

Studies reported measurements related to the need for hospitalization and the observed patterns in patient daily functioning or activity level. Trial reports documented patterns in the rate of hospitalizations caused by worsening heart function. Research examined the observed patterns in major heart-related events within the populations studied.

Evidence for Use in High Blood Pressure (Essential Hypertension)

The research into Coronal for high blood pressure examined factors related to physiological strain, specifically the force exerted on blood vessels. These evaluations primarily involved short-term to intermediate-term randomized, placebo-controlled trials where the medicine was observed in adult populations diagnosed with essential hypertension. Researchers systematically examined outcomes monitoring physiological strain, such as the changes in systolic and diastolic blood pressure readings, and changes in the resting heart rate.

Trial reports described the magnitude of blood pressure readings and the frequency of participants reaching specific pressure levels set by the research protocols. Comparative trials documented the blood pressure patterns observed when comparing this agent against other established classes of anti-hypertensive medications.

What is Still Uncertain in the Research Landscape

The evidence base for Coronal, while extensive, contains clear limitations. Long-term effects are not fully established across all indications, and research exploring the impact beyond two years for some outcomes is less developed. Data for certain groups remain insufficient, meaning the results apply only to the populations studied in the major trials, and extrapolation to patients with complex or severe coexisting conditions may not be fully supported by trial data alone. The research provides context on group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Coronal (FAQ)


Q: How quickly does Coronal start working after I take it?

A: According to the official product information, the maximal effect of the medication on heart-related activity typically occurs within 1 to 4 hours after taking a dose. However, the full, sustained blood pressure-lowering effects are generally observed after about one week of continued use.


Q: Does Coronal cause weight gain or weight loss?

A: While not listed as a common adverse reaction for Coronal itself, regulatory documents note that unusual or sudden weight gain is a serious sign. This change may be associated with signs of fluid retention and potential worsening of heart failure, and is noted as a symptom that should be addressed by a healthcare professional.


Q: Can Coronal be taken with common pain relievers like ibuprofen or naproxen?

A: Taking Coronal with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen may affect its action. Studies and official information indicate that these pain relievers can decrease Coronal's blood pressure-lowering effect, particularly when they are used long-term.


Q: Are there any supplements or vitamins that interact with Coronal?

A: Regulatory documents specifically identify an interaction with the herbal supplement St. John’s Wort, which may reduce the drug's exposure. Official warnings are not universally provided for common vitamins or other supplements, and interactions may be reviewed by a healthcare provider.


Q: Are there dietary restrictions I should know about when taking Coronal?

A: Official documents advise against using grapefruit products and the herbal supplement St. John’s Wort due to known interactions. It is also noted that Coronal's active ingredient should be taken with or without food, depending on the specific formulation being used.


Q: What kind of monitoring (like blood tests or blood pressure checks) is usually needed while on Coronal?

A: Healthcare providers are advised in official documents to monitor vital signs such as heart rate and blood pressure regularly. For certain patients, caution is advised and monitoring is increased when there are existing kidney or liver issues.


Q: What is the half-life of Coronal? (How long does it stay in the body?)

A: The half-life refers to how long it takes for half of the medication to be cleared from the body. The average plasma elimination half-life of Coronal is typically between 9 and 12 hours. This duration may be slightly longer in older adults or in patients with reduced kidney function.


Q: Can Coronal be taken at the same time as my blood pressure medicine?

A: Coronal is sometimes prescribed in combination with other blood pressure medicines. However, official information indicates that combining these agents requires close monitoring because there is an increased risk of side effects like low blood pressure and a slow heart rate.


Q: Is Coronal a generic drug, or is it only available under its brand name?

A: Coronal is the trade name for the active ingredient, Bisoprolol Fumarate. Regulatory and public health information indicates that Bisoprolol Fumarate is widely available as a generic medication in addition to the original brand-name product.


Q: What should I know about driving or operating machinery while taking Coronal?

A: Official patient information notes that driving or operating machinery should be avoided until an individual knows how the medicine affects their alertness, as Coronal may cause dizziness or drowsiness.


Q: Why is Coronal sometimes prescribed for post-MI (heart attack) patients?

A: Coronal is formally approved for the management of stable chronic heart failure and high blood pressure. The evidence base for its use in chronic heart failure includes studies that examine outcomes for patients following a major heart-related event like a heart attack.


Q: Are there different forms of Coronal, such as extended-release or immediate-release?

A: Coronal is typically presented as a standard, film-coated tablet for oral administration. While combination products containing bisoprolol are listed, regulatory documents do not generally describe an extended-release (ER) version of the single-ingredient tablet.


Q: Does Coronal cause mouth dryness?

A: Official patient information for Coronal and its active ingredient, bisoprolol, states that dry mouth is a possible side effect. This is one of several non-gastrointestinal adverse effects that have been reported.


Q: Can Coronal be taken with over-the-counter cough and cold medicines?

A: Certain over-the-counter cough and cold medicines, particularly those containing adrenergic agonists (like decongestants), may reduce Coronal's blood pressure-lowering effects. Regulatory information suggests that these combinations may increase the risk of side effects or reduce the drug's intended action.


Q: What is the general success rate described in studies for people taking Coronal?

A: Regulatory documents summarize that research trials showed Coronal was associated with statistically significant reductions in systolic and diastolic blood pressure in patients with hypertension. In chronic heart failure, studies documented a reduction in major heart-related events within the populations examined.


Q: Why is it important to have regular check-ups when taking Coronal?

A: Regular check-ups are required to allow the healthcare provider to monitor vital signs and assess the medication's effect. This monitoring also helps check for the development of any serious unwanted effects, such as worsening heart failure, which requires immediate attention.


Q: What is the maximum length of time a person can take Coronal?

A: Coronal is typically intended for long-term use for chronic conditions like heart failure and hypertension. Official regulatory documents do not define a specific maximum duration of treatment.


Q: Are there any long-term side effects associated with Coronal?

A: The active ingredient in Coronal has been extensively studied in trials lasting up to two years. Regulatory documents do not categorize side effects based on long-term versus short-term duration, but the major safety considerations and known adverse reactions are fully detailed in the prescribing information.


Q: If I am taking an antidepressant, is it safe to also take Coronal?

A: Regulatory documents advise that co-administration with potent irreversible MAO inhibitors, which are a class of antidepressant, is prohibited. Additionally, official information suggests that other agents that act on the central nervous system may carry an additive sedation risk when taken with Coronal.

How should Coronal be stored and disposed of?

How to Store and Dispose of Coronal?

The storage and disposal of Coronal (Bisoprolol Fumarate) must adhere strictly to regulatory requirements to ensure product stability and safety.

Storage Conditions

Item Official Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F); Do not freeze.
Protection Keep in the original container, tightly closed, and protect from light and moisture.
Safety Mandatory instruction: Keep out of the sight and reach of children.

Disposal Instructions

Expired or unused tablets must not be thrown away via wastewater or household waste. Consult a pharmacist or healthcare professional for instructions on safe disposal according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coronal found in:

A-Z Index: